Costs and quality of life effects of the first year of renal replacement therapy in one Finnish treatment centre

Journal of Medical Economics

Volumn 12, Issue 2, 2009, Pages 136-140

  Hallinen, Taru ^a,b,c   Soini, Erkki J O ^b,c   Martikainen, Janne A ^b   Ikäheimo, Risto ^a,d   Ryynänen, Olli Pekka ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c Esior Oy   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

15D; Costs; Dialysis; End stage renal disease; Quality of life

Indexed keywords

ADULT; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DIALYSIS; FEMALE; FINLAND; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KIDNEY POLYCYSTIC DISEASE; MALE; NEPHROSCLEROSIS; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; SOCIAL INSURANCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

COMMUNITY HEALTH CENTERS; COSTS AND COST ANALYSIS; FEMALE; FINLAND; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RENAL DIALYSIS;

EID: 67749139677     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903119530     Document Type: Article

References (15)

1. Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;17(Suppl 11):8-12. (Pubitemid 35277055)
2. Suomen munuaistautirekisteri, Finnish Registry for Kidney Diseases: Vuosiraportti 2007, Annual Report 2007. Helsinki, 2008.
3. Honkanen EO, Rauta VM. What happened in Finland to increase home hemodialysis? Hemodial Int 2008;12(Suppl 1.:S11-15.
4. Shih Y, Guo A, Just P, et al. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int 2005;68:319-329. (Pubitemid 43181391)
5. Joyce A, Iacoviello J, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-2835. (Pubitemid 39565045)
6. Sandoz M, Ess S, Keusch G, et al. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly 2004;134:448-458.
7. Salonen T, Reina T, Oksa H, et al. Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis 2003;42:1228-1238. (Pubitemid 37486767)
8. Salonen T, Reina T, Oksa H, et al. Alternative strategies to evaluate the cost-effectiveness of peritoneal dialysis and hemodialysis. Int Urol Nephrol 2007;39:289-298. (Pubitemid 46722979)
9. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy 2008;26:85-96. (Pubitemid 351296306)
10. Malmström RK, Roine RP, Heikkilä A, et al. Cost analysis and health-related quality of life of home and self-care satellite haemodialysis. Nephrol Dial Transplant 2008;23:1990-1996. (Pubitemid 351768159)
11. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001;33:328-336. (Pubitemid 32675373)
12. Yildirim A. The importance of patient satisfaction and health-related quality of life after renal transplantation. Transplant Proc 2006;38:2831-2834. (Pubitemid 44737960)
13. Swindle R, VanDensen Lukas C, Meyer DA, et al. Cost analysis in the Department of Veteran Affairs, consensus and future directions. Med Care 1999;37(Suppl):3-8.
14. National Public, Health Institute. The Finnish Health 2000 Survey data. Helsinki, 2006.
15. Saarni SI, Härkänen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ 5D. Qual Life Res 2006;15:1403-1414. (Pubitemid 44673614)